A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
A phase 2 trial of Zilovertamab vedotin, Cyclophosphamide, Doxorubicin, Rituximab and Prednisone in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) is a phase 2 interventional study registered as NCT05406401 by Merck Sharp & Dohme LLC, with 60 participants enrolled, started 2022-07-14 and due to reach its primary completion in 2029-04-26. Interventions recorded: Zilovertamab Vedotin, Cyclophosphamide, Doxorubicin, Rituximab, Rituximab Biosimilar and Prednisone.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Shares Zilovertamab vedotin, Prednisone, Rituximab, Cyclophosphamide and the tag pipeline.
- TrialA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi
Shares Zilovertamab vedotin, Prednisone, Rituximab, Cyclophosphamide.
- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Prednisone, Rituximab, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialSafety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Shares Prednisone, Rituximab, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Shares Zilovertamab vedotin, Merck & Co. (MSD) and the tag pipeline.
- TrialTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Shares Cyclophosphamide, Doxorubicin, Merck & Co. (MSD) and the tag pipeline.